What is the Differential Diagnosis of a Suprarenal Mass?
Discussion
Suprarenal masses (SRM) are not that common (incidence of 1.9/1000 in neonates), but are more commonly diagnosed prenatally because of prenatal ultrasound. Masses can be difficult to accurately diagnose even after birth because their features overlap. Radiographically they can be variable in size, cystic/solid or mixed and with or without calcifications. Common signs and symptoms of SRM include anemia, jaundice, scrotal hematoma and abdominal mass. Signs of asphyxia may also occur. Often patients whose diagnosis is not clear are monitored closely for a few weeks to see how the lesion changes with time. This is e...
Source: PediatricEducation.org - February 5, 2024 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Atlanta cardio-oncologist on why to take cardiovascular health seriously while battling cancer
Chemotherapy, though lifesaving in terms of its cancer-fighting abilities, can wreak havoc on cardiovascular health. In the early 21st century, researchers discovered that adult cancer survivors face about 42% increased risk of cardiovascular disease. This finding has prompted oncologists and cardiologists to work together to reduce heart complications during and after cancer treatment.
Dr. Lalitha Medepalli, a cardio-oncologist with Northside Hospital Heart Institute, shares more details about … (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 1, 2024 Category: Pharmaceuticals Authors: Northside Hospital Source Type: news
Phase I Trial Improves Mesothelioma Survival More Than 200%
Sellas Life Sciences reports its Phase I clinical trial showed improvement of overall survival in patients with pleural mesothelioma. The study focused on a new potential therapy called GPS (galinpepimut-S), an immunotherapy vaccine.
The trial included 10 patients with relapsed or refractory mesothelioma, nine of whom received at least three doses of GPS. Researchers gave the third dose of GPS alongside the checkpoint inhibitor Opdivo (nivolumab).
President of Sellas, Angelos Stergiou, stated in a press release, “As we had hypothesized in the past, this increase in survival appears to be consistent with long-...
Source: Asbestos and Mesothelioma News - January 31, 2024 Category: Environmental Health Authors: Travis Rodgers Tags: Clinical Trials/Research/Emerging Treatments Immunotherapy Mesothelioma Source Type: news
Early Mesothelioma Vaccine Testing Shows Survival Gains
Sellas Life Sciences reports its Phase I clinical trial showed improvement of overall survival in patients with pleural mesothelioma. The study focused on a new potential therapy called GPS (galinpepimut-S), an immunotherapy vaccine.
The trial included 10 patients with relapsed or refractory mesothelioma, nine of whom received at least three doses of GPS. Researchers gave the third dose of GPS alongside the checkpoint inhibitor Opdivo (nivolumab).
President of Sellas, Angelos Stergiou, stated in a press release, “As we had hypothesized in the past, this increase in survival appears to be consistent with long-...
Source: Asbestos and Mesothelioma News - January 31, 2024 Category: Environmental Health Authors: Sean Marchese Tags: Clinical Trials/Research/Emerging Treatments Immunotherapy Mesothelioma Source Type: news
Early Mesothelioma Vaccine Testing Shows Promise
Sellas Life Sciences reports its Phase I clinical trial showed improvement of overall survival in patients with pleural mesothelioma. The study focused on a new potential therapy called GPS (galinpepimut-S), an immunotherapy vaccine.
The trial included 10 patients with relapsed or refractory mesothelioma, nine of whom received at least three doses of GPS. Researchers gave the third dose of GPS alongside the checkpoint inhibitor Opdivo (nivolumab).
President of Sellas, Angelos Stergiou, stated in a press release, “As we had hypothesized in the past, this increase in survival appears to be consistent with long-...
Source: Asbestos and Mesothelioma News - January 31, 2024 Category: Environmental Health Authors: Sean Marchese Tags: Clinical Trials/Research/Emerging Treatments Immunotherapy Mesothelioma Source Type: news
Unlikely Breakthrough of the Year: Chemo for Lung Cancer Unlikely Breakthrough of the Year: Chemo for Lung Cancer
Mark Kris makes the case that chemotherapy is the breakthrough of 2023 for lung cancer.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 31, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
Breast Cancer Gene Test May Lead to Worse Care for Black Patients
WEDNESDAY, Jan. 31, 2024 -- A common genetic test to determine treatment options for breast cancer could be leading some Black patients to forego chemotherapy that might have helped them, a new study says.
The test appears to underestimate the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 31, 2024 Category: General Medicine Source Type: news
Peripheral IV Access for Chemo Better Than Central Lines in Testicular Cancer?
(MedPage Today) -- Patients with testicular cancer had fewer venous access-related complications and overall thrombotic events when first-line chemotherapy was delivered via peripheral intravenous access compared with central venous access devices... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 30, 2024 Category: Hematology Source Type: news
Uncertainty Surrounds Sensitivity of ctDNA in CRC Uncertainty Surrounds Sensitivity of ctDNA in CRC
ctDNA is a useful prognostic tool in CRC, but it ' s unclear whether it can guide the use of adjuvant chemotherapy.MDedge News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 30, 2024 Category: Consumer Health News Tags: Hematology-Oncology Source Type: news
ctDNA-Based Detection of Residual Disease Prognostic for Resected CRC
MONDAY, Jan. 29, 2024 -- For patients with radically resected, stage II to IV colorectal cancer (CRC), circulating tumor (ct)DNA-based detection of molecular residual disease (MRD) in response to adjuvant chemotherapy (ACT) is prognostic of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 29, 2024 Category: Pharmaceuticals Source Type: news
How Much Do Physicians Really Know About FDA Drug and Device Regulation?
(MedPage Today) -- Medications, from blood pressure control to chemotherapy, and medical devices, from hip replacements to heart valves, represent the backbone of healthcare. Ubiquitous in everyday clinical medicine, drugs and devices are only... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - January 28, 2024 Category: American Health Source Type: news
When a Revolutionary Cancer Treatment Causes Cancer
(MedPage Today) -- My patient was young, in his thirties, and had a terrible leukemia that refused to be vanquished with multiple rounds of chemotherapy. Many of my adult patients, at the time of their diagnosis, tell me they are so happy they... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - January 27, 2024 Category: American Health Source Type: news
Liquid Biopsy Has Mixed Performance for Predicting Colon Cancer Outcomes
(MedPage Today) -- SAN FRANCISCO -- In separate studies, liquid biopsy produced mixed results for guiding colon cancer treatment.
Adjuvant chemotherapy guided by postoperative circulating tumor (ct) DNA did not lead to higher rates of DNA clearance... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - January 24, 2024 Category: Gastroenterology Source Type: news
Immunotherapy Combo Wins Big on PFS in First-Line Mets CRC Immunotherapy Combo Wins Big on PFS in First-Line Mets CRC
First-line nivolumab plus ipilimumab led to significantly better 2-year PFS in metastatic CRC than chemotherapy as well as pembrolizumab monotherapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 23, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Hepatic Infusion Pumps: New Enthusiasm for an Old Technology Hepatic Infusion Pumps: New Enthusiasm for an Old Technology
Patients with advanced, unresectable cholangiocarcinoma had significantly better survival outcomes after treatment with hepatic arterial chemotherapy infusion pumps vs standard therapy.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - January 23, 2024 Category: Gastroenterology Tags: Hematology-Oncology Source Type: news
